A. Bertolotti

Long COVID: major findings, mechanisms and recommendations

Leishmaniasis

Inflammation and tumor progression: signaling pathways and targeted intervention

Unexplained post-acute infection syndromes

The JAK/STAT signaling pathway: from bench to clinic

Association of the Endobiont Double-Stranded RNA Virus LRV1 With Treatment Failure for Human Leishmaniasis Caused byLeishmania braziliensisin Peru and Bolivia

Vitiligo

The STING pathway and the T cell-inflamed tumor microenvironment

Cutaneous leishmaniasis: immune responses in protection and pathogenesis

Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity

Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer

Cytomegalovirus, Epstein‐Barr virus, and human herpesvirus‐6 infections in patients with myalgic еncephalomyelitis/chronic fatigue syndrome

Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)

Miltefosine Susceptibility and Resistance in Leishmania: From the Laboratory to the Field

Presence ofLeishmaniaRNA Virus 1 inLeishmania guyanensisIncreases the Risk of First-Line Treatment Failure and Symptomatic Relapse

Rheumatism and chronic fatigue, the two facets of post-chikungunya disease: the TELECHIK cohort study on Reunion island

Type I interferon signature in the initiation of the immune response in vitiligo